Janos Dolgos

Pest, BU, Hungary

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol.

Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol.

Journal: Pathology oncology research : POR

Published: February 05, 2024

Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement.

Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement.

Journal: Pathology oncology research : POR

Published: April 14, 2023

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen.

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen.

Journal: Blood

Published: May 04, 2022

Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.

Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.

Journal: PloS one

Published: February 19, 2021

Importance of next generation sequencing in precision oncology approach of acute myeloid leukemia

Importance of next generation sequencing in precision oncology approach of acute myeloid leukemia

Journal: Magyar onkologia

Published: October 16, 2019

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.

Journal: Haematologica

Published: June 05, 2014

Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort.

Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort.

Journal: Leukemia & lymphoma

Published: October 05, 2013

Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.

Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: October 09, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026